NDAORALTABLET
Approved
Jun 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BAYCOL (cerivastatin sodium) is an oral statin tablet approved in 1997 for lipid management in patients requiring cholesterol reduction. It is a small-molecule HMG-CoA reductase inhibitor that lowers LDL cholesterol and triglycerides. Patients with dyslipidemia and cardiovascular risk factors are the primary target population.
LOE Approaching
Product is in advanced lifecycle stage with moderate competitive pressure (30%), suggesting stabilized or shrinking team headcount focused on market defense.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BAYCOL currently has zero linked job openings, reflecting its mature, stable lifecycle status. Roles focus on market defense and payer negotiation rather than growth initiatives or product expansion.
Brand ManagerField Sales Representative
Worked on BAYCOL at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.